GO
Loading...

Biotechnology

More

  • Arena Pharma's 'Belviq' potential     Monday, 3 Nov 2014 | 2:40 PM ET

    Jack Lief, Arena Pharmaceutical president & CEO, breaks down the company's Q3 earnings and discusses the outlook for its weight loss drug "Belviq."

  • Russia comes to Silicon Valley to recruit Monday, 3 Nov 2014 | 10:52 AM ET
    The Skolkovo Hypercube  in Moscow, Russia.

    Russia has a new tech city chock-full of co-working spaces, seed funding, and a research university. All they need now are the technologists.

  • TOKYO, Oct 30- Japan's Fujifilm Holdings Corp said it was difficult to estimate the profitability of its influenza drug Avigan, which has been earmarked to fight Ebola, given the uncertainty over the spread of virus, a company executive said on Thursday. France and Guinea plan to conduct clinical trials of Avigan 200 mg tablets, made by Fujifilm group company...

  • Bull case for biotech     Monday, 27 Oct 2014 | 11:25 AM ET

    CNBC's Bertha Coombs takes a close look at the wild swings taking place in the biotech sector.

  • Run up in biotech is highly rational: UBS     Wednesday, 22 Oct 2014 | 5:35 AM ET

    Matthew Roden, executive director of biotechnology equity research at UBS argued biotech stock valuations are still attractively valued even after their run higher.

  • Ebola stocks: Who's leading?     Wednesday, 1 Oct 2014 | 2:21 PM ET

    Discussing which biotech companies working on treatments for deadly viruses are the most investable, with Dr. Neil Shahrestani, Pura Vida analyst.

  • GMO 'superseeds' leading to 'superweeds' Tuesday, 30 Sep 2014 | 11:22 AM ET

    The newest batch of crop seeds is setting off another debate over GMOs. This time, they're being blamed for an infestation of "superweeds."

  • Cramer: Stay on biotech     Wednesday, 24 Sep 2014 | 8:51 AM ET

    CNBC's Jim Cramer takes a look at what's putting pressure on the markets and why he is watching the biotech sector.

  • ImClone's Waksal plans IPO     Wednesday, 24 Sep 2014 | 7:31 AM ET

    CNBC's Meg Tirrell reports Sam Waksal is back in the biotechnology industry.

  • Tax crackdown impact on pharma deals     Tuesday, 23 Sep 2014 | 2:45 PM ET

    Discussing how the Treasury Department's new rules to end tax inversions could impact the pharma deals, with Michael Faerm, Wells Fargo Securities.

  • 3 Biotech picks: Gilead, Biogen & Celgene     Friday, 5 Sep 2014 | 12:54 PM ET

    Breaking down the hottest stocks in biotech now, with John Schroer, Allianz Global Investors.

  • Race for cholesterol drugs     Tuesday, 2 Sep 2014 | 8:17 AM ET

    A new class of drugs which aim to lower levels of LDL are being pursued by multiple pharma companies and it could be a $10 billion market. Leonard Schleifer, Regeneron CEO, discusses what is known about bad cholesterol, and competition in the space.

  • Why US biotech stocks are back in favor     Monday, 25 Aug 2014 | 7:16 PM ET

    While biotechnology shares are not cheap, they are nowhere near "bubble-like" valuations, says Bill Stone, Chief Investment Strategist at PNC Asset Management Group.

  • Roche's blockbuster pharma deal     Monday, 25 Aug 2014 | 3:47 PM ET

    CNBC's Meg Tirrell breaks down the mega deal between Swiss pharmaceutical firm Roche and InterMune for $8.3 billion.

  • What Roche gets from InterMune     Monday, 25 Aug 2014 | 10:09 AM ET

    Switzerland's Roche is buying InterMune for $8.3 billion. CNBC's Meg Tirrell reports InterMune's Esbriet drug could draw more than $1 billion in annual revenue.

  • Roche's $8.3 billion deal for InterMune     Monday, 25 Aug 2014 | 9:06 AM ET

    Drug giant Roche is buying biotech firm InterMune for $8.3 billion. CNBC's Jim Cramer discusses the lifesaving drug behind the wave of M&A deals.

  • Big change for pain drugs     Friday, 22 Aug 2014 | 2:12 PM ET

    CNBC's Meg Tirrell reports the Drug Enforcement Administration is changing the rules around pain drugs like Vicodin. The drugs will be deemed "schedule 2 substances," versus the less restrictive "schedule 3."

  • Aug 19- The U.S. government has extended a contract with Cytori Therapeutics to develop a cell-derived treatment for burns, the company said on Tuesday. The government's Biomedical Advanced Research and Development Authority will provide up to $20.4 million to fund early development and costs associated with a clinical trial.

  • Hot biotech drugs     Tuesday, 19 Aug 2014 | 7:07 AM ET

    CNBC's Meg Tirrell reports which biotech drug developments investors are excited about.

  • Fighting obesity with Rxs     Monday, 18 Aug 2014 | 2:17 PM ET

    Zafgen CEO Tom Hughes discusses the company's dedication to tackle obesity, with CNBC's Meg Tirrell. Hughes says the new drug works to impact the way the body handles fat.